Immune Checkpoint Inhibitors Market To Find Better Growth with US$ 40,882.6 Million Threshold By 2026 | CAGR: 11.8%: Coherent Market Insights
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Immune Checkpoint Inhibitors Market, by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 10,543.8 million in 2017 and is estimated to exhibit a CAGR of 11.8% over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2560
The increasing prevalence of cancer, coupled with rising number of drug launches and robust pipelines are the factors that are expected to boost demand for immune checkpoint inhibitors, which is further expected to drive the global immune checkpoint inhibitors market growth over the forecast period. Moreover, major manufacturers are investing into R&D to develop immune-checkpoint therapies by understanding tumor functions and ways to combat them.
Manufacturers are also focusing on upgrading available immune checkpoint inhibitors as well as developing new immune checkpoint inhibitors for cancer treatment. For instance, AstraZeneca’s Durvalumab (Imfinzi) was approved in 2017, as immune checkpoint inhibitor, which blocks interaction of PD-L1 with PD-1 and CD80. Similarly, in December 2017, Bristol-Myers Squibb received approval for Nivolumab (Opdivo), indicated for adjuvant treatment of melanoma. Furthermore, in March 2017, Avelumab (Bavencio), jointly developed by EMD Serono, and Pfizer, Inc. received the U.S. Food & Drug Administration (FDA) approval for the treatment of metastatic merkel cell carcinoma. Additionally, in 2017, the U.S. FDA approved to immunotherapy product- TECENTRIQ (atezolizumab), which is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC).
Browse 46 Market Data Tables and 41 Figures spread through 238 Pages and in-depth TOC on Global Immune Checkpoint Inhibitors Market by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) – Global Forecast to 2026
To know the latest trends and insights prevalent in the Global Immune Checkpoint Inhibitors Market Press Release, click the link below: https://bit.ly/2ROGEPB
The increasing research and development by leading as well as small and mid-sized players in immune checkpoint inhibitors market is expected to drive growth of the global immune checkpoint inhibitors market over the forecast period. For instance, in May 2018, Oncolytics Biotech, Inc. entered into a research collaboration with the Keck School of Medicine of University of Southern California (USC), to develop a combination therapy of Reolycin (Oncolytics Biotech’s product), Keytruda, Velcade, and dexamethasone for the treatment of multiple myeloma. Similarly, in January 2018, Keytruda, developed by Merck & Co. reported slow liver cancer progression in Phase 2 trial. Immuno-oncology combination therapies are also under research for various cancer indications. In January 2018, the U.S. Food & Drug Administration (FDA) granted breakthrough therapy status to Lenvima-Keytruda combo for advanced kidney cancer.
Furthermore, in February 2018, Opdivo-Yervoy combination therapy showed delayed disease progression in patients with advanced non-small cell lung cancer. Moreover, in December 2017, Genentech combination therapy Tecentriq and Avastin delayed kidney cancer progression in Phase III trials. AstraZeneca Plc’s Imfinzi (Durvalumab) showed delayed non-small cell lung cancer progression in Phase III trials in November 2017.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2560
Key Takeaways of the Global Immune Checkpoint Inhibitors Market:
- The global immune checkpoint inhibitors market is expected to exhibit a CAGR of 11.8% over the forecast period. The market growth is attributed to presence of several leading manufacturers, who are engaged on introducing innovative therapies through extensive research and development such as Bristol Myers Squibb, Novartis, and Pfizer, Inc., among others.
- Moreover, biopharmaceutical companies are focusing on developing a robust pipeline of immune-checkpoint inhibitor combination therapies, owing to their increasing demand. The U.S. Food & Drug Administration (FDA) has approved a number of immune checkpoint inhibitors including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1).
- Immuno-checkpoint inhibitor combination therapies are expected to change the market scenario over the forecast period, owing to positive results in the clinical trials
- Increasing number of research partnerships and collaborations to develop new drugs by various market players are further expected to drive growth of the market, as competitors are striving to gain competitive edge in the market
- Key players operating in the global immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2560
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire